Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase II study evaluating the pharmacokinetics, safety and tolerability of the weekly formulation of setmelanotide FluidCrystal and its effect on reducing body weight in healthy individuals

Next Previous
Search
Trial Profile

A phase II study evaluating the pharmacokinetics, safety and tolerability of the weekly formulation of setmelanotide FluidCrystal and its effect on reducing body weight in healthy individuals

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 22 Dec 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Setmelanotide (Primary) ; Setmelanotide
  • Indications Obesity
  • Focus Adverse reactions; Therapeutic Use

    • Most Recent Events

    • 06 Nov 2020 Healthy individuals with obesity initially body mass index [BMI] =40 kg/m2 was amended to BMI =35 kg/m2 to increase recruitment as per results presented at The Obesity Society Annual Meeting Scientific Sessions 2020
    • 06 Nov 2020 Interim results (n=85) presented at The Obesity Society Annual Meeting Scientific Sessions 2020
    • 04 Nov 2020 Interim results (n=85) presented in a Rhythm Media Release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top